Document Detail

Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study.
Jump to Full Text
MedLine Citation:
PMID:  22044595     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previous studies have found associations between the use of central nervous system medication and the risk of cognitive decline in the aged. Our aim was to assess whether the use of a single central nervous system (CNS) medication and, on the other hand, the combined use of multiple CNS medications over time are related to the risk of cognitive decline in an older (≥ 65 yrs) population that is cognitively intact at baseline.
METHODS: We conducted a longitudinal population-based study of cognitively intact older adults. The participants were 65 years old or older and had Mini-Mental State Examination (MMSE) sum scores of 24 points or higher. The study included a 7.6-year follow-up. The use of benzodiazepines and related drugs (BZDs), antipsychotics (APs), antidepressants (ADs), opioids (Ops), anticholinergics (AChs) and antiepileptics (AEs) was determined at baseline and after a 7.6-years of the follow-up period. Cognitive functioning was used as an outcome variable measured with MMSE at baseline and at the mean follow-up of 7.6 years. Control variables were adjusted with analyses of covariance.
RESULTS: After adjusting for control variables, the use of Ops and the concomitant use of Ops and BZDs as well as the use of Ops and any CNS medication were associated with cognitive decline. The use of AChs was associated with decline in cognitive functioning only in men.
CONCLUSIONS: Of all the CNS medications analyzed in this study, the use of Ops may have the greatest effect on cognitive functioning in the ageing population. Due to small sample sizes these findings cannot be generalized to the unselected ageing population. More studies are needed concerning the long-term use of CNS medications, especially their concomitant use, and their potential cognitive effects.
Authors:
Juha Puustinen; Janne Nurminen; Minna Löppönen; Tero Vahlberg; Raimo Isoaho; Ismo Räihä; Sirkka-Liisa Kivelä
Related Documents :
22207915 - Medical bill problems steady for u.s. families, 2007-2010.
25475155 - Establishing medical plausibility in the context of orphan medicines designation in the...
22044595 - Use of cns medications and cognitive decline in the aged: a longitudinal population-bas...
21460725 - Healthcare costs, buyer alert.
10124305 - Decision tree. a process for determining when to withdraw or continue life-sustaining m...
2400795 - Subjective experiences associated with thermal biofeedback treatment of hypertension.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-11-01
Journal Detail:
Title:  BMC geriatrics     Volume:  11     ISSN:  1471-2318     ISO Abbreviation:  BMC Geriatr     Publication Date:  2011  
Date Detail:
Created Date:  2011-11-30     Completed Date:  2012-07-31     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  100968548     Medline TA:  BMC Geriatr     Country:  England    
Other Details:
Languages:  eng     Pagination:  70     Citation Subset:  IM    
Affiliation:
Department of Family Medicine, University of Turku, Turku, Finland. juhpuu@utu.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Analgesics, Opioid / administration & dosage,  adverse effects
Benzodiazepines / administration & dosage,  adverse effects
Brief Psychiatric Rating Scale
Central Nervous System Agents / administration & dosage*,  adverse effects*
Cognition Disorders / chemically induced*,  epidemiology*,  psychology
Cohort Studies
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Longitudinal Studies
Male
Population Surveillance / methods*
Chemical
Reg. No./Substance:
0/Analgesics, Opioid; 0/Central Nervous System Agents; 12794-10-4/Benzodiazepines
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMC Geriatr
ISSN: 1471-2318
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2011 Puustinen et al; licensee BioMed Central Ltd.
open-access:
Received Day: 4 Month: 4 Year: 2011
Accepted Day: 1 Month: 11 Year: 2011
collection publication date: Year: 2011
Electronic publication date: Day: 1 Month: 11 Year: 2011
Volume: 11First Page: 70 Last Page: 70
ID: 3226547
Publisher Id: 1471-2318-11-70
PubMed Id: 22044595
DOI: 10.1186/1471-2318-11-70

Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study
Juha Puustinen1234 Email: juhpuu@utu.fi
Janne Nurminen1345 Email: janurm@utu.fi
Minna Löppönen13 Email: minlop@utu.fi
Tero Vahlberg6 Email: tervah@utu.fi
Raimo Isoaho1 Email: raimiso@utu.fi
Ismo Räihä1 Email: iraiha@utu.fi
Sirkka-Liisa Kivelä178 Email: sirkiv@utu.fi
1Department of Family Medicine, University of Turku, Turku, Finland
2Unit of Neurology, Satakunta Central Hospital, Pori, Finland
3Härkätie Health Centre, Lieto, Finland
4Turku University Central Hospital, Turku, Finland
5Turku Health Centre, Turku, Finland
6Department of Biostatistics, University of Turku, Turku, Finland
7Unit of Family Medicine, Turku University Central Hospital, Turku, Finland
8Satakunta Central Hospital, Pori, Finland

Background

Epidemiological studies have produced evidence of the relationship between the use of psychotropic drugs and the risk of cognitive decline in the aged populations [1,2]. Long-term use of benzodiazepines (BZDs) has been suggested to increase the risk of cognitive decline or dementia in the aged [3-6]. It has also been suggested that the use of anticholinergic medications (AChs) may be related to the risk of cognitive deterioration in the aged [7-11].

A majority of the studies have examined the association between a single group of medications with effects on the central nervous system (CNS) and cognitive decline. Our literature search in PubMed produced only one study [2] about the concomitant use of several CNS medications and the risk of cognitive decline. The results of the study showed that the combined use of CNS medications was associated with cognitive decline in older adults who were cognitively intact at baseline [2].

We decided to test the hypothesis whether the use of one CNS medication or, in particular, the use of a combination of two or more CNS medications predict decline in cognitive functioning among older persons who are cognitively healthy at baseline.


Methods
Participants

The sample of this longitudinal population-based study comprised participants of the longitudinal Lieto study. The population in the first phase of the Lieto study consisted of all the residents in the municipality of Lieto born in 1926 or earlier (N = 1,283) being aged 65 or older in the study year. Of these, 1,196 (93%, 488 men and 708 women) participated [12-15]. The sample of our study comprised the participants of the first phase of the Lieto study [12-15] who scored 24 to 30 sum points in the Mini-Mental State Examination (MMSE) [16] and who were alive and participated in the second phase of the longitudinal Lieto study (N = 565; 227 men and 338 women). The first phase of the Lieto study was carried out between 1 October, 1990, and 31 December, 1991, and the second phase between 1 March, 1998, and 31 September, 1999 [12-15]. Thus, the mean follow-up time was 7.6 ± 0.5 years (range 6.4-9.1 years).

Methods and measures

During both phases of the Lieto study all participants were interviewed about their socioeconomic background, physical and psychosocial factors, functional abilities, use of medications and health behaviour. They were also clinically examined by a health centre physician who was part of the research team (RI or ML). Clinical tests were performed by a trained research nurse. Medical records in the Härkätie Health Centre, Lieto, were used in recording previous diagnoses. Similar measures were used in both phases.

Cognitive functioning was measured during both phases with an MMSE performed by a trained nurse. The MMSE scale consists of 23 items, and the sum score ranges from 0 to 30, higher scores indicating better cognitive performance [16]. The mean change in MMSE sum scores during the follow-up was used as an outcome variable.

Information about the use of all medications prior to seven days before the interview was collected in a personal interview conducted by a trained nurse at the baseline and follow-up interviews to describe the total medication at both data collection phases. The participants had been informed to bring along their prescription forms and medications in order to confirm their current use of medication. A health centre physician from the research team (RI or ML) verified the medications from medical records. In cases where the person interviewed was unable to answer questions adequately, a close relative or caregiver provided the relevant information. If the participant was unable to visit the health centre, a trained nurse made a home visit to check the medications. All the prescribed medications (both regular and irregular) and non-prescribed medications (vitamins etc.) were taken into account.

Medications were defined by using the Anatomical Therapeutic Chemical (ATC) Classification (1996) [17]. The groups of medications defined as those with an effect on the central nervous system (CNS) and used in the analyses of this study were as follows: benzodiazepines and related drugs (BZDs) (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71), antipsychotics (APs) (ATC codes N05A, N06CA01), antidepressants (ADs) (ATC codes N06A, N06CA), opioids (Ops) (ATC codes N01AH, N02A, N02BE51, R05DA, R05FA), anticholinergic medications (AChs) (ATC codes N04A, N05AA01, N05AA02, N05AB01, N05AB02, N05AB03, N05AB04, N05AC01, N05AC02, N05AF01, N05AF03, N05AF05, N05BB01, N06AA04, N06AA06, N06AA09, N06AA12, 102AG, A03AA, A03AB, A03AX03, A03B, A03CA, A03CB31, A03DA, A03FA01, A04AD01, A04AD12, C01BA01, C01BA03, C01BA51, C01BA71, R03BB, M03B, G04BD, S01FA, R01BA01, R01BA51, R06AB01, R06AE03, R06AE53) and antiepileptic medications (AEs) (ATC code N03A) [18,19].

The usages of these groups of CNS medications were first dichotomized (regular or irregular use vs. no use). The doses of the medications were not taken into account. Eight variables describing the use of CNS medications were then formed: BZDs, APs, ADs, psychotropics (including BZDs, APs or ADs), Ops, AChs, AEs and any CNS medications (including BZDs, APs, ADs, Ops, AChs or AEs). Finally, 21 variables describing all combinations of the CNS medications were formed.

Previously known risk factors of cognitive decline [20] such as age, sex, basic education, hypertension, atrial fibrillation or flutter, diabetes mellitus, congestive heart disease and smoking at the baseline were used as control factors. Interviews were used in collecting data about basic education and current smoking. Hypertension, diabetes and congestive heart disease were defined according to clinical examination, medical history or previous diagnoses in the medical records. The diagnosis of atrial fibrillation or flutter was based on a diagnosis in the medical records or on electrocardiograms (ECG) recorded during the baseline examination.

Informed consent was obtained from all participants or their caregivers in both phases of the study. The study plans of the first and second Lieto studies were approved by the Ethical Committee of the Hospital District of Southwest Finland.

Statistical analyses

The analyses were performed for the total population and separately for men, women and younger (65-74 yrs) and older (≥ 75 yrs) age groups. Participants who at the beginning of the follow-up were using one type of the CNS medications described in the methods and measures section were first compared with participants who did not use any of these medications at baseline and then with participants not using the medication concerned. Participants using a combination of two or more of the CNS medications were compared with participants using none of the CNS medications or their combinations.

Chi-square and Fisher exact tests were used to test differences in categorical variables between sexes, age groups and, diagnoses as well as between medication users and control groups at baseline and during the follow-up examination. The significances of changes in MMSE sum scores during the follow-up in the total population and in all subgroups were tested using the Wilcoxon signed rank test. The differences of the mean MMSE sum scores, the mean ages and the mean number of medications and the changes of mean MMSE sum scores between the groups were tested with the Mann-Whitney U test. Associations between the use of a certain group of CNS medications or the use of a combination of CNS medications and the risk of cognitive decline were first analyzed by the Mann-Whitney U test. The significances of the differences in the changes of cognitive functioning during the follow-up between the users of a certain group of CNS medications or the users of a combination of CNS medications and the corresponding control group of nonusers were first tested with the Mann-Whitney U test. After these analyses, adjusted analyses using the analysis of covariance were performed for those groups in which the associations between the use of a certain CNS medication or the concomitant use of certain CNS medications and the risk for cognitive decline were significant (p < 0.05) or tended to be significant (0.05 < p < 0.10) in these bivariate analyses. The associations of these variables (age, sex, education, hypertension, atrial fibrillation or flutter, diabetes mellitus, congestive heart disease and smoking at baseline) with the decline in MMSE sum scores were first analyzed in the total population, and only the variables that were significantly associated with decline (higher age, p < 0.001, and congestive heart disease, p = 0.002) were adjusted in the analyses of covariance.


Results
Background data

The majority (n = 439; 77.7%) of the participants completing the follow-up were aged 64 to74 years at baseline, and 126 (22.3%) were 75 years or older. The mean age was 70.5 years (range 64 to 89).

Of the participants, 357 (63.2%) were married, 147 (26.0%) unmarried or divorced, and 61 (10.8%) widowed. Altogether 393 participants (69.6%) lived at home with another person or other people, 169 (29.9%) lived alone, and 3 (0.5%) were institutionalized. 32 (5.7%) had received less than basic education, 484 (85.7%) basic education and 49 (8.7%) more than basic education. 523 (92.7%) were able to walk independently, 40 (7.1%) with an assisting device, and 1 (0.2%) with the help of another person. The mean number ± SD of prescribed medications used regularly was 1.9 ± 2.2, and that of medications used irregularly (as needed) was 0.6 ± 1.0.

Use of CNS medications

At baseline, 20% of the participants used BZDs and 14% used AChs, while APs, ADs, Ops and AEs were used only by some participants (Table 1). At least one CNS medication was used by one third of the participants. The use of BZDs was more common in women than in men (25.1% vs. 13.2%, p < 0.001). The use of BZDs was more common among the older age group than among the younger one (34.1% vs. 16.4%, p < 0.001). APs were also more commonly used by older participants compared to the younger ones (8.7% vs. 3.9%, p = 0.027). Women used CNS medications more commonly than men (35.5% vs. 22.5%, p < 0.001), and the older age group more commonly than the younger one (43.7% vs. 26.4%, p < 0.001). Varying according to the medication group, 33 to 74% of participants used their medication at both the baseline and follow-up examination.

The use of combinations of the CNS medications included in the analyses was not common at baseline (Table 2). The most common combinations were BZDs and AChs (5.7% of the participants) and APs and AChs (3.9%).

Changes in cognitive functioning during follow-up

During the follow-up period, cognitive functioning declined significantly in the total population as well as in all the subgroups (Table 3).

Background data and the use of CNS medications

The persons who used CNS medications also used more other medications than the non-users (Table 4). Compared to the group of non-users, the users of CNS medications included more women, persons living alone, persons needing tools for walking, and persons suffering from depression, hypertension or transient ischemic attacks.

CNS medications and their combinations and cognitive change
One CNS medication

The users of at least one CNS medication were first compared to those using no CNS medications. The second control group consisted of non-users of the CNS medications examined. The use of any kind of a CNS medication at baseline was associated with cognitive decline in the bivariate analysis (p = 0.041), but the relationship did not remain significant after adjusting for control variables. The use of Ops at baseline was associated with cognitive decline in the older age group, and the use of AChs in men (Table 5). These relationships were observable even after adjusting for control variables.

Combinations of CNS medications

The combination of BZDs and Ops was associated with cognitive decline among all participants and among women. The association remained significant after adjusting for control variables. The combination of Ops and any CNS medication was associated with cognitive decline among all participants. The association remained significant after adjusting for control variables.


Discussion

Our results show that Ops and the combined use of Ops and BZDs or any CNS medications were associated with cognitive decline. In addition, we discovered that the use of AChs was associated with the risk of cognitive decline in men.

Strengths and limitations

The complete follow-up data were obtained for 565 participants, and the material may be considered a middle-sized cohort. The longitudinal population-based design and a high participation rate (93% of the total aged population) are major methodological strengths of this study.

Medication history and clinical background data were reliably recorded. The measure of cognitive functioning (MMSE) is a frequently used instrument for assessing global cognitive functioning. It measures general cognitive performance. The MMSE cut off point 24/23 provides a sensitivity of 69% and a specificity of 99% for dementia [21]. Only the persons who were cognitively intact at baseline were included in the study population. The diagnoses of the participants obtained from the medical records of the health centre showed that cognitive impairment was not diagnosed in any of the participants using BZDs, APs, ADs, Ops, AChs or AEs at baseline.

Many potential risk factors for cognitive decline such as age, sex, education, hypertension, atrial fibrillation or flutter, diabetes mellitus, congestive heart disease and smoking at baseline could be adjusted for as control factors. Even with adjustment, observational epidemiologic studies can only show associations between risk factors and outcome, whereas exploration of causalities requires a randomized study design. However, long-lasting randomized and controlled trials with exposure to harmful effects of medications are not possible. Due to the observational, longitudinal design and small sample sizes, these findings cannot be directly generalized to an unselected ageing population using Ops or AChs, but more studies among elderly long-term Op or ACh users with larger sample sizes are needed to confirm this association.

We adjusted the results for several potential risk factors of cognitive decline, but were unable to use some medical or other conditions (e.g., the use of alcohol) as adjusting variables. The use of alcohol was not measured during the first phase; therefore, we could not use this measure as a control variable. Studies about the use of alcohol among older Finns in the late 1980s have shown that the use diminishes with increasing age, and few older people, mainly men, are heavy users of alcohol [22].

The use of CNS medications was not common among our participants, and the concomitant use of several CNS medications was quite rare. These facts have affected the strength of the statistical tests, especially when analyzing the data by sex and age. Only baseline medication data were used in the analyses. New medications may have been prescribed and previous ones may have been given up during the follow-up period. Previous results have shown that psychotropics, especially benzodiazepines, are commonly used for years [14,15,23]. In our study, from one third to two thirds of those using a certain CNS medication at baseline used similar medication at the time of the follow-up examination. This supports the hypothesis that quite a few participants used these medications during the whole follow-up period and were real long-term users.


Results

The use of Ops predicted cognitive decline during the long follow-up period. We have not found previous studies of possible long-term effects of Ops on cognitive functioning in the aged. Ops used by our aged population were codeine (N = 3), dextropropoxyphene (N = 2), ethylmorphine (N = 2) and dextrometorphan (N = 2). The diagnoses of the users of Ops showed that these medications were used for painful arthrotic diseases. Nobody was diagnosed to suffer from cancer pain. Despite the small number of users of these medications, a relationship was found between the use of Ops and cognitive decline suggesting that the use of Ops has a negative effect on cognitive functioning. The single use of BZDs, ADs or APs was not related to the risk of cognitive decline. These relationships are previously studied mainly for the use of BZDs, and the results are controversial [3-6,24,25]. Two small experimental randomized, controlled studies showed no cognitive decline in short-term use of APs among cognitively intact persons [26,27]. In our study, the combination of BZDs or any CNS medication and Ops was related to the risk of cognitive decline. These findings support the idea that the use of a psychotropic medication alone does not inevitably effect cognitive functioning, but combining this kind of a medication with Ops may be harmful.

The use of AChs was related to the risk of cognitive decline in men. Here our results are in concordance with the results of previous studies about the use of AChs as a risk factor for cognitive decline among unselected cognitively intact older persons [7-11]. In our population, more men than women used anticholinergic psychotropics with high CNS affinity [28], while women used more commonly urge incontinence medications targeted to have peripheral effects [28]. The blood-brain barrier permeability of different anticholinergic medications may differ depending on molecules [28], age [29] or disease states [30], which might explain why the risk of cognitive deterioration was detected only among men.

The number of persons using two or more CNS medications concomitantly was small. This possesses statistical limitations. Negative results may be caused by the rather small sample size and the small number of users. Due to a lack of statistical power, negative results do not prove that CNS medications are not related to the risk of cognitive decline. Positive results, however, show strong associations in this sample. In clinical settings, the aged using these medications should be monitored more carefully to detect the cognitive decline associated to the use of the medications.


Conclusions

The use of anticholinergics and opioids alone and the use of opioids with benzodiazepines or any psychotropic medication or any CNS medication are associated with cognitive decline in an older cognitively intact population. However, studies with larger sample sizes and about possible pathophysiologic mechanisms are needed.


Competing interests

This study was financially supported by the 19th February Fund of the Finnish Heart Association; the Finnish Academy; the Federation of Municipalities of Härkätie, Lieto, Finland; Turku University Hospital Grant EVO; Satakunta Hospital District Grant EVO; Finnish Association for General Practice; Uulo Arhio Foundation and Finnish Cultural Foundation. All authors of the article are independent from funders and have no conflicts of interest.

JP has lectured on further education courses for physicians, nurses and physiotherapists sponsored by Janssen-Cilag, Lundbeck and Novartis. JN has no competing interests. ML has lectured on further education courses for physicians, nurses and physiotherapists sponsored by Janssen-Cilag, Lundbeck, Novartis and Pfizer. TV, RI and IR have no competing interests. SLK has given lectures on further education courses for physicians, nurses and physiotherapists sponsored by Janssen-Cilag, Pfizer, Lundbeck, Novartis and Leiras.

The funding institutes had no role in study design, data collection, analysis, or interpretation or in the preparation of the manuscript for publication.


Authors' contributions

JP conceptualized the study, formulated the hypothesis, designed the study, performed the literature review, analyzed the data, and drafted and revised the manuscript. JN formulated the hypothesis, designed the study, analyzed the data, and, drafted and revised the manuscript. ML collected the data (second phase), designed the study, and drafted and revised the manuscript. TV designed the study, consulted in the statistical design, and drafted and revised the manuscript. RI designed the study, collected the data (first and second phase), and drafted and revised the manuscript. IR analyzed the data, and drafted and revised the manuscript. SLK conceptualized the study, formulated the hypothesis, designed the study, supervised the data collection, analyzed the data, and drafted and revised the manuscript. All authors have read and approved the final manuscript.


Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2318/11/70/prepub


Acknowledgements

The authors would like to thank ADP designers Jukka Saukkoriipi and Teemu Kemppainen for their valuable work in performing the statistical analyses, informatician Juha Hartikainen, MSc (Tech), and librarian Katri Haapaniemi for assisting in performing searches in scientific literature, translator Liisa Punkka, M.A., for proof-reading the manuscript, project secretary Selena Nitecki and office secretary Ritva Kultalahti for their assistance in the writing process.


References
Berg S,Dellasega C,The use of psychoactive medications and cognitive function in older adultsJ Aging HealthYear: 19968113614910.1177/08982643960080010710160568
Wright RM,Roumani YF,Boudreau R,Newman AB,Ruby CM,Studenski SA,Shorr RI,Bauer DC,Simonsick EM,Hilmer SN,Hanlon JT,Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the Health, Aging And Body Composition StudyJ Am Geriatr SocYear: 200957224325010.1111/j.1532-5415.2008.02127.x19207141
Bierman EJ,Comijs HC,Gundy CM,Sonnenberg C,Jonker C,Beekman AT,The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent?Int J Geriatr PsychiatryYear: 200722121194120010.1002/gps.181117407168
Paterniti S,Dufouil C,Alperovitch A,Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging StudyJ Clin PsychopharmacolYear: 200222328529310.1097/00004714-200206000-0000912006899
Lagnaoui R,Begaud B,Moore N,Chaslerie A,Fourrier A,Letenneur L,Dartigues JF,Moride Y,Benzodiazepine use and risk of dementia: a nested case-control studyJ Clin EpidemiolYear: 200255331431810.1016/S0895-4356(01)00453-X11864804
Hanlon JT,Horner RD,Schmader KE,Fillenbaum GG,Lewis IK,Wall WE,Landerman LR,Pieper CF,Blazer DG,Cohen HJ,Benzodiazepine use and cognitive function among community-dwelling elderlyClin Pharmacol TherYear: 199864668469210.1016/S0009-9236(98)90059-59871433
Carriere I,Fourrier-Reglat A,Dartigues JF,Rouaud O,Pasquier F,Ritchie K,Ancelin ML,Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city studyArch Intern MedYear: 2009169141317132410.1001/archinternmed.2009.22919636034
Han L,Agostini JV,Allore HG,Cumulative anticholinergic exposure is associated with poor memory and executive function in older menJ Am Geriatr SocYear: 200856122203221010.1111/j.1532-5415.2008.02009.x19093918
Ancelin ML,Artero S,Portet F,Dupuy AM,Touchon J,Ritchie K,Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort studyBmjYear: 2006332753945545910.1136/bmj.38740.439664.DE16452102
Basu R,Dodge H,Stoehr GP,Ganguli M,Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognitionAm J Geriatr PsychiatryYear: 200311220521312611750
Bottiggi KA,Salazar JC,Yu L,Caban-Holt AM,Ryan M,Mendiondo MS,Schmitt FA,Long-term cognitive impact of anticholinergic medications in older adultsAm J Geriatr PsychiatryYear: 2006141198098410.1097/01.JGP.0000224619.87681.7117068321
Isoaho R,Puolijoki H,Huhti E,Kivela SL,Tala E,Prevalence of asthma in elderly FinnsJ Clin EpidemiolYear: 199447101109111810.1016/0895-4356(94)90097-37722544
Lopponen M,Raiha I,Isoaho R,Vahlberg T,Kivela SL,Diagnosing cognitive impairment and dementia in primary health care -- a more active approach is neededAge AgeingYear: 200332660661210.1093/ageing/afg09714600001
Linjakumpu T,Hartikainen S,Klaukka T,Koponen H,Kivela SL,Isoaho R,Psychotropics among the home-dwelling elderly--increasing trendsInt J Geriatr PsychiatryYear: 200217987488310.1002/gps.71212221663
Linjakumpu T,Hartikainen S,Klaukka T,Veijola J,Kivela SL,Isoaho R,Use of medications and polypharmacy are increasing among the elderlyJournal of clinical epidemiologyYear: 200255880981710.1016/S0895-4356(02)00411-012384196
Folstein MF,Folstein SE,McHugh PR,"Mini-mental state". A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr ResYear: 197512318919810.1016/0022-3956(75)90026-61202204
National Agency of MedicinesClassification of Medicines (ATC) and Defined Daily Doses (DDD)Year: 1996Helsinki
SocialstyrelsenIndikatorer för utvärdering av kvaliteten i äldres läkemedelsterapi [Indicators for evaluating the quality of medication therapy in the aged]Year: 2003Stockholm Report No.: 2003-110-20: 74.
Fick DM,Cooper JW,Wade WE,Waller JL,Maclean JR,Beers MH,Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of expertsArch Intern MedYear: 2003163222716272410.1001/archinte.163.22.271614662625
Qiu C,De Ronchi D,Fratiglioni L,The epidemiology of the dementias: an updateCurr Opin PsychiatryYear: 200720438038510.1097/YCO.0b013e32816ebc7b17551353
Tangalos EG,Smith GE,Ivnik RJ,Petersen RC,Kokmen E,Kurland LT,Offord KP,Parisi JE,The Mini-Mental State Examination in general medical practice: clinical utility and acceptanceMayo Clin ProcYear: 199671982983710.4065/71.9.8298790257
Kivela SL,Nissinen A,Ketola A,Punsar S,Puska P,Karvonen M,Changes in alcohol consumption during a ten-year follow-up among Finnish men aged 55-74 yearsFunct NeurolYear: 1988321671783402816
Puustinen J,Nurminen J,Kukola M,Vahlberg T,Laine K,Kivela SL,Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: a non-randomised clinical study in the elderlyDrugs AgingYear: 200724121045105910.2165/00002512-200724120-0000718020536
Dealberto MJ,McAvay GJ,Seeman T,Berkman L,Psychotropic drug use and cognitive decline among older men and womenInt J Geriatr PsychiatryYear: 199712556757410.1002/(SICI)1099-1166(199705)12:5<567::AID-GPS552>3.0.CO;2-V9193967
Fastbom J,Forsell Y,Winblad B,Benzodiazepines may have protective effects against Alzheimer diseaseAlzheimer Dis Assoc DisordYear: 1998121141710.1097/00002093-199803000-000029539405
Legangneux E,McEwen J,Wesnes KA,Bergougnan L,Miget N,Canal M,L'Heritier C,Pinquier JL,Rosenzweig P,The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteersJ PsychopharmacolYear: 200014216417110.1177/02698811000140020610890311
Allain H,Tessier C,Bentue-Ferrer D,Tarral A,Le Breton S,Gandon M,Bouhours P,Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteersPsychopharmacology (Berl)Year: 20031654419429
Todorova A,Vonderheid-Guth B,Dimpfel W,Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous systemJ Clin PharmacolYear: 200141663664410.1177/0091270012201052811402632
Pakulski C,Drobnik L,Millo B,Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrierMed Sci MonitYear: 20006231431811208329
Starr JM,Wardlaw J,Ferguson K,MacLullich A,Deary IJ,Marshall I,Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imagingJ Neurol Neurosurg PsychiatryYear: 2003741707610.1136/jnnp.74.1.7012486269

Tables
[TableWrap ID: T1] Table 1 

Use of CNS medications.


Medication Number of users
Baseline Follow-up Both baseline and follow-up
N % N % N % of users at baseline
Opioids 9 2 43 7 3 33
Anticholinergics 78 14 104 18 37 47
Antiepileptics 7 1 7 1 3 43
Benzodiazepines or related drugs 115 20 181 32 84 73
Antipsychotics 28 5 36 6 11 39
Antidepressants 19 3 71 13 14 74
At least one CNS medication 171 30 262 46 133 78

Number (%) of participants using CNS medication at the baseline and follow-up examinations and number of participants using these medications both at baseline and during follow-up.

CNS = central nervous system


[TableWrap ID: T2] Table 2 

Use of combinations of CNS medications


Combinations of medications Sex Age
Both Men Women 65-74 75+
(N = 565) (N = 227) (N = 338) (N = 439) (N = 126)
N % N % N % N % N %
Opioid and
 anticholinergic 1 0.2 0 0 1 0.3 1 0.2 0 0
 antiepileptic 0 0 0 0 0 0 0 0 0 0
 benzodiazepine or related drug 4 0.7 0 0 4 1.2 1 0.2 3 2.4
 antipsychotic 2 0.4 0 0 2 0.6 2 0.5 0 0
 antidepressant 1 0.2 0 0 1 0.3 1 0.2 0 0
 any of the above drugs 6 1.1 0 0 6 1.8 3 0.7 3 2.3
Anticholinergic and
antiepileptic 1 0.2 1 0.4 0 0 0 0 1 0.8
 benzodiazepine or related drug 32 5.7 11 4.8 21 6.2 19 4.3 13 10.3
 antipsychotic 22 3.9 6 2.6 16 4.7 13 3.0 9 7.1
 antidepressant 9 1.6 3 1.3 6 1.8 8 1.8 1 0.8
 any of the above drugs 48 8.5 15 6.6 33 9.8 31 7.1 17 13.5
Antiepileptic and
 antidepressant 0 0 0 0 0 0 0 0 0 0
 benzodiazepine or related drug 3 0.5 3 1.3 0 0 2 4.6 1 0.8
 antipsychotic 1 0.2 1 0.4 0 0 0 0 1 0.8
 any of the above drugs 3 0.5 3 1.3 0 0 2 0.5 1 0.8
Benzodiazepine or related drug and
 antipsychotic 13 2.3 5 2.2 8 2.4 7 1.6 6 4.8
 antidepressant 12 2.1 2 0.9 10 3.0 9 2.1 3 2.4
 any of the above drugs 46 8.1 14 6.2 32 9.5 28 6.4 18 14.3
Antipsychotic and
 antidepressant 5 0.9 1 0.4 4 1.2 3 0.7 2 1.6
 any of the above drugs 28 5.0 7 3.1 21 6.2 17 3.9 11 8.7
Antidepressant and
 any of the above drugs 19 3.4 4 1.8 15 4.4 15 3.4 4 3.2

Number and proportion of participants using a combination of CNS medications at baseline, by sex and age.

CNS = central nervous system


[TableWrap ID: T3] Table 3 

Cognitive functioning


Population MMSE sum score
At baseline After 7.6-year follow-up p-value1
(1990-1991) (1998-1999)
Mean ± SD Mean ± SD
Total population (N = 565) 28.1 ± 1.9 26.1 ± 4.8 < 0.001
Men (N = 227) 28.3 ± 1.7 26.7 ± 3.4 < 0.001
Women (N = 338) 27.9 ± 2.0 25.7 ± 3.6 < 0.001
64-74 yrs (N = 439) 28.2 ± 1.8 26.9 ± 3.6 < 0.001
≥75 yrs (N = 126) 27.5 ± 2.0 23.3 ± 6.7 < 0.001

Cognitive functioning as measured by the Mini-Mental State Examination (MMSE) at baseline and after a 7.6-year follow-up, by sex and age.

1significance of difference between baseline and follow-up, Wilcoxon signed rank test

SD = standard deviation


[TableWrap ID: T4] Table 4 

Background data and the use of CNS medications


CNS medication users
(N = 171)
CNS medication non-users
(N = 394)
Background variable Mean ± SD Mean ± SD p-value1
Age 71.9 ± 5.7 69.9 ± 4.9 < 0.001
Number of all medications 4.5 ± 2.7 1.6 ± 1.9 < 0.001
Number of regularly taken medications 3.3 ± 2.5 1.3 ± 1.7 < 0.001
Number of medications taken as needed 1.2 ± 1.2 0.3 ± 0.7 < 0.001
Number of all medications excluding CNS medications 3.2 ± 2.5 1.6 ± 1.9 < 0.001
Number of regularly taken medications excluding CNS medications 2.4 ± 2.1 1.3 ± 1.7 < 0.001
Number of medications taken as needed excluding CNS medications 0.8 ± 1.0 0.3 ± 0.7 < 0.001

N % N % p-value2

Sex (woman) 120 70.2 218 55.3 < 0.001
Marital status
 Married 15 8.8 46 11.7 0.076
 Unmarried or divorced 101 59.1 256 65.0
 Widowed 55 32.2 92 23.4
Place of living
 At home alone 64 37.4 105 26.6 0.007
 At home with other person 105 61.4 288 73.1
 In institution or nursing home 2 1.2 1 0.3
Education
 Less than basic 13 7.6 19 4.8 0.423
 Basic 144 84.2 340 86.3
 More than basic 14 8.2 35 8.9
Ability to walk
 Independent 148 86.5 375 95.2 < 0.001
 With tools 22 12.9 18 4.6
 Needs to be assisted 0 0 1 0.3
Diagnoses
 Depression 38 22.2 25 6.4 < 0.001
 Alcohol related disease 1 0.6 5 1.3 0.673
 Hypertension 59 34.5 100 25.4 0.027
 Hypercholesterolemia 32 18.7 60 15.2 0.303
 Diabetes mellitus (type I or II) 7 4.1 25 6.3 0.288
 TIA 8 4.7 3 0.8 0.004
 Cerebral infarct 1 0.6 3 0.8 1.000
 Cerebral haemorrage 1 0.6 1 0.3 0.514
 Cerebral trauma 2 1.2 4 1.0 1.000
 Malignant tumour or cancer 5 0.3 17 4.3 0.432
 HIV, lues or borreliosis 0 0 0 0 1.000
 Dementia (all types) 2 1.2 0 0 0.091

Background data compared between the users and non-users of CNS medications, at baseline.

1significance of difference between users and non-users, Mann-Whitney U

2significance of difference between users and non-users, chi-square test or Fisher's exact test

CNS = central nervous system

SD = standard deviation

TIA = transient ischaemic attack

HIV = human immunodeficiency virus


[TableWrap ID: T5] Table 5 

Use of CNS medication and the change in cognitive functioning


Medication Sex Baseline MMSE MMSE during follow-up Change in MMSE
Users Controls Users Controls Users Controls
N Mean ± SD N Mean ± SD p1 Mean ± SD2 Mean ± SD2 p2 Mean ± SD Mean ± SD p for diff adjusted p
Opioids1 M+W 9 27.7 ±
1.8
384 28.2 ±
1.8
0.276 21.2 ±
7.8
26.5 ±
4.5
0.011 -6.4 ±
7.3
-1.7 ±
4.3
0.007 0.032
Opioids2 M+W 9 27.7 ±
1.8
556 28.1 ±
1.9
0.372 21.2 ±
7.8
26.2 ±
4.7
0.018 -6.4 ±
7.3
-1.9 ±
4.4
0.009 0.021
Anticholinergics2 M 29 28.2 ±
1.8 ±
198 28.3 ±
1.7
0.938 25.0 ±
4.4
27.0 ±
3.2
0.015 -3.2 ±
4.0
-1.3 ±
2.9
0.021 0.002

Opioid and
 any other CNS medication1 M+W 6 27.3 ±
2.0
384 28.2 ±
1.8
0.020 18.8 ±
8.7
26.5 ±
4.5
0.010 -8.5 ±
8.0
-1.7 ±
4.3
0.004 0.007
Benzodiazepine or related drug and
 opioid1 M+W 4 26.5 ±
1.7
384 28.2 ±
1.8
0.052 15.8 ±
8.7
26.5 ±
4.5
0.004 -10.8 ±
9.0
-1.7 ±
4.3
0.006 0.002
 opioid1 W 4 26.5 ±
1.7
210 28.0 ±
2.0
0.097 15.8 ±
8.7
26.0 ±
5.2
0.007 -10.8 ±
9.0
-2.0 ±
5.1
0.010 0.024

Significant associations between the use of at least one CNS medication or the use of a combination of CNS medications and change in cognitive functioning (MMSE) during the follow-up of 7.6 years (1990-1999), by sex.

M = men

W = women

MMSE = Mini-Mental State Examination

SD = standard deviation

p1 = significance of difference in MMSE at baseline between users and controls, Mann-Whitney U test

p2 = significance of difference in MMSE during follow-up examination between users and control, Mann-Whitney U test

p for diff = significance of difference of change in MMSE between users and controls, Mann-Whitney U test

adjusted p = p-value for difference of change in MMSE between users and controls adjusted for control factors, analysis of covariance

1control group: no medication with effects on the central nervous system

2control group: non-users of corresponding medications



Article Categories:
  • Research Article


Previous Document:  Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases.
Next Document:  Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispens...